2019 miRNA Market Forecasts and Antisense and RNAi Therapeutics Analysis in New Global Research Reports

DALLAS, November 13, 2014 /PRNewswire/ --

RnRMarketResearch.com adds Global miRNA Market 2015-2019 and Global Antisense and RNAi Therapeutics Market 2015-2019 research reports to its biotechnology industry intelligence collection. Global miRNA market is forecast to grow at a CAGR of 13.36% whereas Antisense and RNAi Therapeutics market is set to grow at 26.79% CAGR over the period 2014-2019.

The Global miRNA market is divided into different segments based on application: miRNA Research, miRNA-based Diagnostics, and Therapeutics. miRNAs are single-stranded, small, non-coding RNA molecules that regulate gene expression at the translation level. They play a vital role in research, diagnostics, and therapeutics to study expression of genes and to control diseases by gene silencing. They interact with mRNA molecules and regulate expression of genes by mRNA cleavage, translational repression, and deadenylation. They are generally 17-27 nucleotides long and regulate post-transcriptional mRNA expression by binding to the 3′ untranslated region of the mRNA sequence, which results in translational suppression and gene silencing. miRNAs are involved in a wide range of biological processes, including apoptosis, cell cycle control, and several developmental processes such as stem cell differentiation, hypoxia, hematopoiesis, neurogenesis, insulin secretion, cardiac and skeletal muscle development, aging, cholesterol metabolism, viral replication, and immune responses. They can be used as therapeutics for the treatment of some severe diseases including cancer and genetic disorders by introducing specific miRNAs into diseased cells to silence the defective gene.

The Global miRNA Market 2015-2019 research report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global miRNA market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Companies like Affymetrix, Agilent Technologies, Exiqon, Qiagen, Thermo Fisher Scientific, Alnylam Pharmaceuticals, Aparna Biosciences, Applied Biological Materials, AstraZeneca Pharmaceuticals, Biogen Idec, Bio-Rad Laboratories, F. Hoffmann-La Roche, Firefly Bioworks, Fluidigm, Genecopoeia, Genosensor, Gensignia, Glaxosmithkline, Groove Biopharma, HTG Molecular Diagnostics, Idera Pharmaceuticals, Illumina, Integrated DNA Technologies, InteRNA Technologies, LC Sciences, EMD Millipore, Miltenyi Biotec, miRagen Therapeutics, Mirna Therapeutics, Nanostring Technologies, Norgen Biotek, Novartis, Origene Technologies, Pfizer, Phalanx Biotech, Prolias Technologies, Quark Pharmaceuticals, Regulus Therapeutics, Rosetta Genomics, RXi Pharmaceuticals, Sanofi, Santaris Pharma (Acquired by Roche), Silence Therapeutics, System Biosciences, Takara Bio, Tekmira Pharmaceuticals, Theradiag, WaferGen Biosystems and Wako Pure Chemical Industries are discussed in this research available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=240330 .

Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.

The Global Antisense and RNAi Therapeutics Market 2015-2019 research report calculates the market size by considering the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including: Infectious diseases, Cardiovascular diseases, Kidney diseases, Cancer, Metabolic disorders and Others. The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics. It has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Companies like Alnylam Pharmaceuticals, Isis Pharmaceuticals, Sanofi, Tekmira Pharmaceuticals, Acuitas Therapeutics, Allergan, Antisense Therapeutics, Ascletis, AstraZeneca, Atlantic Pharmaceuticals, Benitec Biopharma, Biogen Idec, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Dicerna Pharmaceuticals, Enzon Pharmaceuticals, F. Hoffmann-La Roche, Glaxosmithkline, Gradalis, iCo Therapeutics, Kyowa Hakko Kirin, Marina Biotech, Novartis, OncoGenex Pharmaceuticals, OPKO Health, Pfizer, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, Spectrum Pharmaceuticals, Sylentis, Takeda Pharmaceutical, Teva Pharmaceutical, The Medicines Company and TransDerm are discussed in this research available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=240338 .

Explore more reports on the RNAi technology market and other therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us: 

RnRMarketResearch.com is an online database of market research reports and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED